Our ability to provide a multi-faceted approach to formulation and cGMP compliance is of critical value to our customers as there are many unknowns through all the stages of the product development process. With extensive experience in research, formulation, analytics and advanced manufacturing, our world-class scientific team understands the challenges and complexities of providing regulatory conforming clinical materials.
The SARS-CoV2 pandemic highlighted the need for proven and effective approaches to vaccine development. It is important to note that USSF has been working in partnership with Vaxform to develop vaccines since its inception in 2013.
USSF Vaccine Products
- SARS‐CoV‐2 oral vaccine (pre-clincal)
- Group A Strep injectable vaccine
- Pertussis (Whooping Cough) oral vaccine
US Specialty Formulations’ Covid-19 oral vaccine mentioned in a press conference with congresswoman Susan Wild and Dr. Ashih Jha. Excerpts from the press conference are featured in the video below:
USSF Oral Covid-19 Vaccine Cleared for Phase One Clinical Trials
Allentown, PA, May 25, 2021 — US Specialty Formulations (USSF), a cGMP pharmaceutical manufacturer, and VaxForm, a vaccine development company, announced positive results from pre-clinical safety and immunological studies for their oral-dosage COVID-19 vaccine, demonstrating the formulation is safe to proceed to human clinical trials.Read More